Companies › Rigel Pharmaceuticals
3 active drug programs in 13 registered trials: 7 Phase 2, 4 Phase 1, 2 Phase 4; Oncology, Other, Hematology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Olutasidenib Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor | IDH1 | Phase 4 | AML (Acute Myeloid Leukemia); High Grade Glioma; Targeted Therapy; Myelodysplastic Syndromes … | Apr 2027 |
| Pralsetinib Tyrosine-protein kinase receptor RET inhibitor; Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor | RET, CCDC6, KIF5B | Phase 4 | NSCLC (Non-small Cell Lung Cancer) | Jul 2027 |
| R906289 Monosodium (R289 Na) | – | Phase 1 | Low Risk Myelodysplastic Syndromes | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07411586 | Olutasidenib | Phase 1 | Acute Myeloid Leukemia | Oncology | Jan 2027 |
| NCT06543381 | Olutasidenib | Phase 1 | Acute Myeloid Leukemia | Oncology | Feb 2027 |
| NCT07486713 | Olutasidenib | Phase 4 | AML (Acute Myeloid Leukemia) | Oncology | Apr 2027 |
| NCT07032727 | Olutasidenib | Phase 2 | Targeted Therapy | Oncology | Jun 2027 |
| NCT06445959 | Olutasidenib | Phase 1 | Mutant IDH1 Inhibitor Olutasidenib | Other | Jun 2027 |
| NCT07704658 | Pralsetinib | Phase 4 | NSCLC (Non-small Cell Lung Cancer) | Oncology | Jul 2027 |
| NCT06566742 | Olutasidenib | Phase 2 | Myelodysplastic Syndromes | Oncology | Aug 2027 |
| NCT07304011 | Olutasidenib | Phase 2 | Acute Myeloid Leukemia | Oncology | Dec 2027 |
| NCT05308264 | R906289 Monosodium (R289 Na) | Phase 1 | Low Risk Myelodysplastic Syndromes | Hematology | Dec 2027 |
| NCT06668584 | Olutasidenib | Phase 2 | Myeloid Malignancies | Oncology | Dec 2027 |
| NCT07471841 | Olutasidenib | Phase 2 | IDH1 Mutation | Oncology | Jun 2028 |
| NCT06782542 | Olutasidenib | Phase 2 | Acute Myeloid Leukemia | Oncology | Mar 2029 |
| NCT06161974 | Olutasidenib | Phase 2 | High Grade Glioma | Oncology | Jun 2029 |
Cash and short-term investments of $99m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Nuvation Bio Nurix Therapeutics Compass Therapeutics Dizal Pharmaceuticals Shanghai Kechow Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.